Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    "Herpes Simplex" | "Protective Agents"

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02715752
Recruitment Status : Completed
First Posted : March 22, 2016
Last Update Posted : April 26, 2016
Sponsor:
Information provided by (Responsible Party):
The Center for the Biology of Chronic Disease

Brief Summary:
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Condition or disease Intervention/treatment
Herpes Simplex Infections Human Papillomavirus Epstein-Barr Virus Infections Varicella-zoster Virus Infection Cytomegalovirus Infections Dietary Supplement: Gene-Eden-VIR/Novirin

Detailed Description:
The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
Study Start Date : January 2016
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Herpes Simplex Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Human Papillomavirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Epstein-Barr Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Cytomegalovirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin
Varicella Zoster Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary Supplement: Gene-Eden-VIR/Novirin



Primary Outcome Measures :
  1. frequency of symptoms [ Time Frame: one year ]
  2. duration of symptoms [ Time Frame: one year ]

Secondary Outcome Measures :
  1. time to first recurrence [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Men and women ages greater than 18 years old
Criteria

Inclusion Criteria:

  • Latent viral infection with either HSV, HPV, VZV, EBV, or CMV
  • Taking Gene-Eden-VIR/Novirin

Exclusion Criteria:

  • Use of other antiviral treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02715752


Locations
Layout table for location information
United States, New York
The Center for the Biology of Chronic Disease
Valley Cottage, New York, United States, 10989
Sponsors and Collaborators
The Center for the Biology of Chronic Disease

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: The Center for the Biology of Chronic Disease
ClinicalTrials.gov Identifier: NCT02715752     History of Changes
Other Study ID Numbers: 022015
First Posted: March 22, 2016    Key Record Dates
Last Update Posted: April 26, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Herpes Simplex
Protective Agents
Infection
Communicable Diseases
Herpes Zoster
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Varicella Zoster Virus Infection
Virus Diseases
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Tumor Virus Infections
Selenium
Quercetin
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Trace Elements
Micronutrients
Nutrients
Growth Substances